Inhibrx Biosciences ratios data for the quarter ended Jun 2026. These financial ratios cover 12 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||
| EBT Margin | -156,823.33% | -43,518.49% | -5,628.76% | 1,858,013.00% | -47,865.00% | -2,204.00% | ||||||
| EBIT Margin | -137,796.67% | -38,510.08% | -5,403.24% | -160,898.00% | -49,928.00% | -2,106.85% | ||||||
| EBITDA Margin | -137,796.67% | -38,510.08% | -5,403.24% | -160,898.00% | -49,928.00% | -2,106.85% | ||||||
| Operating Margin | -137,796.67% | -38,510.08% | -5,403.24% | -160,898.00% | -49,928.00% | -2,106.85% | ||||||
| Net Margin | -156,840.00% | -43,520.17% | -5,628.52% | 1,858,011.00% | -47,865.00% | -2,204.15% | ||||||
| FCF Margin | -46,062.18% | -3,688.07% | -59,517.00% | -43,839.00% | -2,304.54% | |||||||
| Efficiency | ||||||||||||
| Assets AverageAssets Avg. | 240.49M | 201.66M | 211.70M | 227.38M | 194.79M | 161.97M | 150.35M | |||||
| Invested CapitalInvested Cap. | 250.47M | 219.37M | 178.47M | 133.58M | 193.10M | 167.84M | 136.75M | 108.55M | 123.31M | |||
| Asset Utilization RatioAsset Util. | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Leverage & Solvency | ||||||||||||
| Interest Coverage RatioInterest Cover | -5.23 | -5.62 | -10.74 | -9.08 | -30.01 | -15.95 | -8.72 | -10.63 | -9.71 | -5.65 | ||
| Debt Ratio | 0.67 | 0.41 | 0.47 | 0.56 | 0.69 | 1.14 | ||||||
| Times Interest Earned | -5.23 | -5.62 | -10.74 | -9.08 | -30.01 | -15.95 | -8.72 | -10.63 | -9.71 | -5.65 | ||
| Valuation | ||||||||||||
| Price to EarningsP/E | 0.11 | -5.17 | -4.66 | -4.68 | -7.21 | -13.85 | -35.07 | -38.03 | ||||
| Price to SalesP/S | 0.00M | 0.00M | 158.90 | |||||||||
| Price to BookP/B | 0.94 | 1.27 | 1.67 | 2.14 | 3.01 | 13.26 | 144.08 | -26.31 | ||||
| Enterprise Value | -21.78M | 30.36M | 70.33M | -14.00M | 19.97M | 335.20M | 1,027.41M | 1,260.33M | ||||
| EV to EBIT | 0.14 | -0.65 | -1.41 | 0.33 | -0.73 | -9.91 | -33.22 | -39.20 | ||||
| EV to EBITDA | 0.14 | -0.65 | -1.41 | 0.33 | -0.73 | -9.91 | -33.22 | -39.20 | ||||
| Market Capitalization | 205.12M | 226.69M | 222.93M | 202.52M | 206.57M | 488.30M | 1,151.63M | 1,393.67M | ||||
| Price to FCFP/FCF | -3.45 | -7.49 | -5.09 | -5.65 | -6.90 | -14.41 | -38.23 | |||||
| EV to FCF | 0.37 | -1.00 | -1.60 | 0.39 | -0.67 | -9.89 | -34.11 | |||||
| EV to CFO | 0.38 | -1.00 | -1.61 | 0.39 | -0.67 | -9.91 | -34.11 | |||||
| Return Ratios | ||||||||||||
| Return on Sales [ROS]ROS | -137,796.67% | -38,510.08% | -5,403.24% | -160,898.00% | -19,957.31% | -49,928.00% | -2,106.85% | -11,002.14% | -9,644.64% | -9,559.46% | ||
| Return on Capital Employed [ROCE]ROCE | -188.30% | -205.95% | -178.82% | -88.63% | -96.99% | -105.34% | -101.62% | |||||
| Return on Invested Capital [ROIC]ROIC | -185.91% | -212.43% | -183.99% | -92.55% | -101.14% | -110.09% | -107.20% | |||||
| Return on Assets [ROA]ROA | 683.38% | 836.82% | 813.86% | -71.99% | -79.62% | -86.47% | -88.72% |